← Back to blog
Getting Started7 min read

Dual GLP-1/GIP Receptor Agonists for Weight Loss: What UK Patients Need to Know

Dual GLP-1/GIP receptor agonists have produced the largest weight loss results of any approved medicine in clinical trials. Here is a thorough, evidence-based guide for UK patients considering this class of treatment.

What are dual GLP-1/GIP receptor agonists?

Dual GLP-1/GIP receptor agonists are a class of once-weekly injectable medicines licensed in the UK for chronic weight management in adults with obesity or overweight with weight-related health conditions. They were approved by the MHRA for weight management and represent the most effective class of prescription weight management medicine currently available.

How do they work?

These medicines activate two receptors simultaneously: the GLP-1 (glucagon-like peptide-1) receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. Both GLP-1 and GIP are naturally occurring gut hormones released after eating. By activating both receptors, these medicines produce a more pronounced effect on appetite suppression, calorie intake, and metabolic function than medicines that act on GLP-1 alone.

The key effects include:

  • Significantly reduced appetite and food cravings
  • Slowed gastric emptying, increasing the feeling of fullness after meals
  • Improved insulin sensitivity and blood glucose regulation
  • Reduced fat storage, particularly visceral fat

What do the clinical trials show?

The SURMOUNT clinical trial programme provides the most comprehensive evidence for this class of medicine in weight management:

  • SURMOUNT-1 — In adults with obesity or overweight without diabetes, participants taking the highest dose achieved an average weight loss of 22.5% of body weight over 72 weeks. Over a third of participants lost 25% or more of their body weight.
  • SURMOUNT-2 — In adults with type 2 diabetes, average weight loss was 15.7% at the highest dose — substantially greater than any previously approved medicine for this population.
  • SURMOUNT-4 — Participants who continued treatment maintained their weight loss, while those switched to placebo regained approximately two-thirds of the weight lost.

What are the available doses?

Treatment is started at a low dose and increased gradually to minimise side effects. The dose is escalated over several months, with each dose held for at least four weeks before increasing. Not everyone needs to reach the maximum dose; the target dose is the highest that is well tolerated and producing the desired effect.

What are the common side effects?

The most common side effects are gastrointestinal and include nausea, vomiting, diarrhoea, constipation, and reduced appetite. These are most pronounced when starting treatment or increasing the dose, and typically improve over time. Starting at a low dose and escalating slowly is the most effective way to minimise these effects. Serious side effects are uncommon but include pancreatitis, gallbladder problems, and — in those with a relevant personal or family history — thyroid tumours.

Is this treatment available on the NHS?

As of 2026, this class of medicine is available through NHS specialist weight management services in England for eligible patients, subject to local commissioning decisions. Access through NHS primary care remains limited. Many patients access treatment through regulated private medical weight loss services while NHS provision expands.

Book a consultation with Weight Loss Wales to discuss whether this treatment is appropriate for you.

Medical disclaimer: The information in this article is for general educational purposes only and does not constitute medical advice. It should not replace a consultation with a qualified healthcare professional. If you have concerns about your health or weight, please speak to your GP or a specialist.

Want personalised support?

Our doctor-led team can help you create a plan that works for you. A clinician will contact you within 12 hours.

Start your consultation